Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)

Next Previous
Search
Trial Profile

Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Etoposide; Filgrastim; Filgrastim; Folinic acid; Folinic acid; Hydrocortisone; Ifosfamide; Imatinib; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Methylprednisolone; Pegaspargase; Prednisone; Prednisone; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 01 Mar 2021 Results (n=4; 3 patients were treated with imatinib and chemotherapy in NCT00720109 and 1 patient was enrolled on AALL1631 Arm B with the COG chemotherapy backbone (NCT03007147)) assessing concurrent imatinib dosing with high-dose methotrexate leads to acute kidney injury and delayed methotrexate clearance in pediatric patients with philadelphia chromosome positive B-cell acute lymphoblastic leukemia, published in the Journal of Pediatric Hematology/Oncology
    • 04 Apr 2020 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2015 Interim results in 60 patients in cohorts 1 and 2 presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top